Yao Binxi, Zhang Haoxiang, Liang Xi, Zhao Tianhe, Hu Jingnan, Ge Jianli, Han Yan, Wang Wenshu, Xu Wenzhong, He Jianming
Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine, Hebei University of Chinese Medicine Shijiazhuang 050011, Hebei, China.
Department of Respiratory, Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China.
Am J Transl Res. 2024 Nov 15;16(11):7016-7035. doi: 10.62347/JGIB9696. eCollection 2024.
With clinical trials on the use of different modern precise radiotherapy techniques in the setting of postoperative radiotherapy (PORT) in N2 non-small cell lung cancer (NSCLC) accumulating, an updated meta-analysis was performed.
A literature search identified studies that investigated PORT versus non-PORT in N2 NSCLC patients. Overall survival (OS) and locoregional recurrence (LR) were employed. The hazard ratio (HR) and relative risk (RR) with 95% confidence interval (CI) were analyzed.
Overall, 33 studies comprised 8653 patients in the PORT group and 12398 in the non-PORT group. The HR for OS was 0.95 [95% CI: 0.91-0.98, P: 0.0009]. HRs of studies employing conventional radiotherapy, 3-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) were 0.90 [95% CI: 0.78-1.04, P: 0.16], 0.82 [95% CI: 0.72-0.93, P: 0.002] and 0.77 [95% CI: 0.64-0.91, P: 0.003], respectively. All HRs favor the PORT group. The RR for LR was 0.56 [95% CI: 0.49-0.65, P<0.00001]. RRs of studies employing conventional radiotherapy, 3D-CRT and IMRT were 0.61 [95% CI: 0.50-0.75, P<0.00001], 0.58 [95% CI: 0.46-0.72, P<0.00001] and 0.58 [95% CI: 0.45-0.73, P<0.00001], respectively.
PORT using 3D-CRT or IMRT benefits patients with N2 NSCLC in terms of LR and OS. PORT using conventional radiotherapy significantly decreases LR while it does not significantly increase OS.
随着在N2期非小细胞肺癌(NSCLC)术后放疗(PORT)中使用不同现代精确放疗技术的临床试验不断积累,进行了一项更新的荟萃分析。
通过文献检索确定了研究N2期NSCLC患者PORT与非PORT的研究。采用总生存期(OS)和局部区域复发(LR)。分析了95%置信区间(CI)的风险比(HR)和相对风险(RR)。
总体而言,33项研究中PORT组有8653例患者,非PORT组有12398例患者。OS的HR为0.95[95%CI:0.91 - 0.98,P:0.0009]。采用传统放疗、三维适形放疗(3D - CRT)和调强放疗(IMRT)的研究的HR分别为0.90[95%CI:0.78 - 1.04,P:0.16]、0.82[95%CI:0.72 - 0.93,P:0.002]和0.77[95%CI:0.64 - 0.91,P:0.003]。所有HR均有利于PORT组。LR的RR为0.56[95%CI:0.49 - 0.65,P<0.00001]。采用传统放疗、3D - CRT和IMRT的研究的RR分别为0.61[95%CI:0.50 - 0.75,P<0.00001]、0.58[95%CI:0.46 - 0.72,P<0.00001]和0.58[95%CI:0.45 - 0.73,P<0.00001]。
使用3D - CRT或IMRT的PORT在LR和OS方面使N2期NSCLC患者受益。使用传统放疗的PORT显著降低LR,但未显著提高OS。